Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene.
OBJECTIVE
To evaluate the effect of atorvastatin on bone mass and markers of bone remodeling in patients with acute coronary syndrome according to the Lys656Asn leptin receptor gene polymorphism.


METHODS
Sixty-two patients with acute coronary syndrome were included. Patients were allocated to low and high doses of atorvastatin according to baseline levels of cholesterol and triglycerides and the index of vascular risk and were studied at hospital admission and at 12 months. Cholesterol, triglycerides, total calcium, phosphorus, magnesium, osteocalcin and urinary deoxypyridinoline were determined in all patients at baseline and at 12 months of follow up. Densitometric studies were conducted in the lumbar spine and hip. Patients with a T-score<-2.5 were considered osteoporotic. The Lys656Asn leptin receptor gene polymorphism was determined by PCR.


RESULTS
Forty-two patients were Lys/Lys homozygotic and 20 Lys/Asn heterozygotic. The prevalence of osteoporosis was 31% for the Lys/Lys genotype and 27% for the Lys/Asn genotype with no significant differences between groups. There was a significant increase in bone mineral density in the lumbar spine (1.117 +/- 0.24 versus 1.135 +/- 0.24, P = 0.008) in patients with the Lys/Lys genotype.


CONCLUSIONS
Atorvastatin increases lumbar spine bone mineral density only in patients with the Lys/Lys genotype of the Lys656Asn polymorphism.
Pérez-Castrillón
José Luis
JL
Internal Medicine Department, Rio Hortega University Hospital, Faculty of Medicine, Valladolid, Spain.
Vega
Gemma
G
Abad
Laura
L
Sanz-Cantalapiedra
Alberto
A
Sagredo
Manuel Gonzalez
MG
De Luis
Daniel
D
Duenas-Laita
Antonio
A
D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000235:genetics*; D000368:Aged; D000069059:Atorvastatin; D015519:Bone Density / Q000187:drug effects / Q000235:genetics*; D016723:Bone Remodeling / Q000187:drug effects / Q000235:genetics*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000235:genetics; D011110:Polymorphism, Genetic; D011758:Pyrroles / Q000627:therapeutic use*; D054411:Receptors, Leptin / Q000235:genetics*
D006538:Heptanoic Acids; D011758:Pyrroles; D054411:Receptors, Leptin; D000069059:Atorvastatin